Currently out of the existing stock ratings of Li Watsek, 91 are a BUY (95.79%), 4 are a HOLD (4.21%).

Li Watsek

Work Performance Price Targets & Ratings Chart

Analyst Li Watsek, currently employed at CANTOR FITZGERALD, carries an average stock price target met ratio of 37.59% that have a potential upside of 43.69% achieved within 171 days.

Li Watsek’s has documented 165 price targets and ratings displayed on 20 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on ASND, Ascendis Pharma AS at 13-Oct-2025.

Wall Street Analyst Li Watsek

Analyst best performing recommendations are on FATE (FATE THERAPEUTICS).
The best stock recommendation documented was for CRVS (CORVUS PHARMACEUTICALS) at 8/3/2021. The price target of $5 was fulfilled within 45 days with a profit of $2.9 (138.1%) receiving and performance score of 30.69.

Average potential price target upside

of $139.3 (67.61%) on APTO (APTOSE BIOSCIENCES).
of $50.47 (47.04%) on ASND (ASCENDIS PHARMA AS).
of $20.05 (72.21%) on VINC (VINCERX PHARMA).

CRVS Corvus Pharmaceuticals SLS Sellas Life Sciences Group AFMD Affimed NV VINC Vincerx Pharma ARVN Arvinas ASND Ascendis Pharma AS PRTG Portage Biotech ONCT Oncternal Therapeutics NKTX Nkarta APTO Aptose Biosciences GBT Global Blood Therapeutics ALXO Alx Oncology Holdings BCYC Bicycle Therapeutics Ltd FATE Fate Therapeutics KURA Kura Oncology RCUS Arcus Biosciences CRIS Curis IDYA Ideaya Biosciences YMAB Y mAbs Therapeutics REPL Replimune Group

Show more stocks

Analyst name

Rating

Rating initiation date

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score